The human proteome is the major source of therapeutic targets and, as such, understanding the causal consequences of varying protein levels has the capacity to identify new target-indication pairs and additional or alternative indications for existing therapeutics. Recent advances in protein measurement have enabled large-scale genome-wide investigations of components of the human plasma proteome. Here, we employed two-sample Mendelian randomization (MR) to evaluate the influence of 968 genetically-influenced plasma protein levels on 153 diseases and 72 quantitative risk factors from MR-Base.